Market Overview

UPDATE: J.P. Morgan Reiterates Neutral Rating, Raises PT on HCP on Model Update

Related HCP
Survey Shows Strong Improvement in Sustainability in Real Estate Industry
HCP-Brookdale Closes $1.2B CCRC JV Deal; Will It Benefit?

In a report published Friday, J.P. Morgan reiterated its Neutral rating on HCP (NYSE: HCP), and raised its price target from $48.00 to $50.00.

J.P. Morgan noted, “We retain our Neutral rating on HCP due to a number of factors. On the valuation front, the stock trades at slight premiums to the health care REIT averages (particularly on an AFFO basis), which we do believe is justified considering its improved growth profile following recent investment activity and lease restructuring. However, we continue to maintain our bias toward more economically leveraged property types at this point in the cycle.”

HCP closed on Thursday at $48.88.

Latest Ratings for HCP

DateFirmActionFromTo
Aug 2014BarclaysMaintainsEqual-weight
May 2014CitigroupMaintainsEqual-weight
Nov 2013Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for HCP
View the Latest Analyst Ratings

Posted-In: J.P. MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (HCP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters